About Tome Biosciences
Tome Biosciences is a company based in Cambridge (United States) founded in 2021. Tome Biosciences has raised $213 million across 2 funding rounds from investors including Fujifilm, ARE and Bruker. Tome Biosciences has completed 1 acquisition, including Replace Therapeutics. Tome Biosciences operates in a competitive market with competitors including Senti Biosciences, Poseida Therapeutics, ADARx Pharmaceuticals, CRISPR Therapeutics and Aldevron, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$213 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
-
Investors
Fujifilm
& 7 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Tome Biosciences
Unlock access to complete
Funding Insights of Tome Biosciences
Tome Biosciences has successfully raised a total of $213M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tome Biosciences
Tome Biosciences has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Fujifilm, ARE and Bruker.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked |
Investor details for Tome Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tome Biosciences
Tome Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Replace Therapeutics.
Investment portfolio details for Tome Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
CRISPR-based genome editing platform is developed for genetic diseases.
|
Locked | Locked | 0 | Locked |
Complete acquisition details for Tome Biosciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Tome Biosciences
Detailed financials for Tome Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tome Biosciences Comparisons
Peer comparison for Tome Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tome Biosciences
Tome Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Poseida Therapeutics, ADARx Pharmaceuticals, CRISPR Therapeutics and Aldevron, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts
|
|
| Locked | Locked | Locked |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing.
|
|
| Locked | Locked | Locked |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| Locked | Locked | Locked |
Therapeutics for molecular-level cancer treatment are developed.
|
Detailed competitors of Tome Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tome Biosciences
Complete news archive for Tome Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tome Biosciences
Tome Biosciences was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Tome Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Mike Lucero is the current CEO of Tome Biosciences.
Tome Biosciences is a funded company, having raised a total of $213M across 2 funding rounds to date.
Tome Biosciences was founded in 2021 and is headquartered in Cambridge, United States. A gene insertion platform is developed by the company within the biotechnology sector, focusing on genomic medicines. CRISPR technologies are employed to integrate any genetic sequence into any genome. This approach supports the creation of treatments for patients via genomic medicines and advanced cell therapies. Operations center on research and development for therapeutic applications.
Tome Biosciences's top competitors include CRISPR Therapeutics, Senti Biosciences and Poseida Therapeutics.
Tome Biosciences has made 1 acquisition, including Replace Therapeutics.
Tome Biosciences has 8 investors. Key investors include Fujifilm, ARE, Bruker, Arch Venture Partners, and Andreessen Horowitz.